C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab [Yahoo! Finance]
C4 Therapeutics, Inc. (CCCC)
NASDAQ:AMEX Investor Relations:
ir.chinacache.com
Company Research
Source: Yahoo! Finance
to enroll 100 patients to detect a =40% response rate , with investigator-assessed responses possible in H2 2027 and centrally assessed readouts around mid-2028. In a heavily pretreated Phase 1 population (median seven prior lines), cemsidomide showed a 53% response rate at the highest exposure and a manageable safety profile (microgram dosing, ~ 48-hour half-life ), and a Phase 1b combo with Pfizer's elranatamab is planned to improve depth of response. The EGFR L858R degrader CFT8919 has Phase 1 China data expected this quarter with a company decision due this month on whether to pursue development or partner, while C4 reports just under $300 million of runway through the end of Interested in C4 Therapeutics, Inc.? Here are five stocks we like better. MarketBeat Week in Review – 12/18 - 12/22 C4 Therapeutics (NASDAQ:CCCC) outlined near-term clinical plans for its targeted protein degradation pipeline during a presentation at Barclays' 28th Annual Global Healthcare Conferenc
Show less
Read more
Impact Snapshot
Event Time:
CCCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CCCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CCCC alerts
High impacting C4 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CCCC
News
- C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact [Seeking Alpha]Seeking Alpha
- C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data [Yahoo! Finance]Yahoo! Finance
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference [Yahoo! Finance]Yahoo! Finance
CCCC
Earnings
- 2/26/26 - Beat
CCCC
Sec Filings
- 3/9/26 - Form 144
- 2/26/26 - Form S-8
- 2/26/26 - Form 10-K
- CCCC's page on the SEC website